JP2023503320A - 肝臓ｘ受容体アゴニストとしての１，２，４－オキサジアゾール誘導体 - Google Patents

肝臓ｘ受容体アゴニストとしての１，２，４－オキサジアゾール誘導体 Download PDF

Info

Publication number
JP2023503320A
JP2023503320A JP2022529931A JP2022529931A JP2023503320A JP 2023503320 A JP2023503320 A JP 2023503320A JP 2022529931 A JP2022529931 A JP 2022529931A JP 2022529931 A JP2022529931 A JP 2022529931A JP 2023503320 A JP2023503320 A JP 2023503320A
Authority
JP
Japan
Prior art keywords
methyl
trifluoromethyl
phenyl
phenoxy
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503320A5 (https=
Inventor
ディー． ボス，ケリー
ファン，イ
ネサンソン フライア，アレック
ハーディー，デクラン
ファン，ジホン
テイラー ライケンス，キャサリン
クリストファー ローレン，ジョン
マ，フペン
モルテニ，バレンティナ
ショー，ダンカン
スミス，ジェフリー
フックズ ソロベイ，キャサリン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023503320A publication Critical patent/JP2023503320A/ja
Publication of JP2023503320A5 publication Critical patent/JP2023503320A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022529931A 2019-11-25 2020-11-23 肝臓ｘ受容体アゴニストとしての１，２，４－オキサジアゾール誘導体 Pending JP2023503320A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940061P 2019-11-25 2019-11-25
US62/940,061 2019-11-25
US202063106293P 2020-10-27 2020-10-27
US63/106,293 2020-10-27
PCT/IB2020/061053 WO2021105857A1 (en) 2019-11-25 2020-11-23 1,2,4-oxadiazole derivatives as liver x receptor agonists

Publications (2)

Publication Number Publication Date
JP2023503320A true JP2023503320A (ja) 2023-01-27
JP2023503320A5 JP2023503320A5 (https=) 2023-11-29

Family

ID=73654860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529931A Pending JP2023503320A (ja) 2019-11-25 2020-11-23 肝臓ｘ受容体アゴニストとしての１，２，４－オキサジアゾール誘導体

Country Status (22)

Country Link
US (2) US11427586B2 (https=)
EP (1) EP4065228A1 (https=)
JP (1) JP2023503320A (https=)
KR (1) KR20220106778A (https=)
CN (1) CN114746149A (https=)
AU (1) AU2020394597B2 (https=)
BR (1) BR112022009942A2 (https=)
CA (1) CA3157657A1 (https=)
CL (1) CL2022001323A1 (https=)
CO (1) CO2022006645A2 (https=)
CR (1) CR20220227A (https=)
DO (1) DOP2022000107A (https=)
EC (1) ECSP22040362A (https=)
IL (1) IL291958A (https=)
JO (1) JOP20220124A1 (https=)
MX (1) MX2022006151A (https=)
PE (1) PE20221785A1 (https=)
PH (1) PH12022551248A1 (https=)
PY (1) PY2077235A (https=)
TW (1) TW202132289A (https=)
UY (1) UY38964A (https=)
WO (1) WO2021105857A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518128A (ja) * 2021-05-20 2024-04-24 ノバルティス アーゲー ３－（（３－（４－（２－（イソブチルスルホニル）フェノキシ）－３－（トリフルオロメチル）フェニル）－１，２，４－オキサジアゾール－５－イル）メチル）－５，５－ジメチル－１－（２－モルホリノエチル）イミダゾリジン－２，４－ジオンの製剤
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
KR102882404B1 (ko) 2022-10-28 2025-11-06 (주)케이메디켐 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036530A1 (en) * 2011-09-08 2013-03-14 Allergan, Inc. 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators
WO2015187840A2 (en) * 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
JP2022514257A (ja) 2018-12-13 2022-02-10 アイノス，インコーポレイテッド ドライアイ疾患の治療のための局所点眼製剤におけるｌｘｒアゴニスト

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036530A1 (en) * 2011-09-08 2013-03-14 Allergan, Inc. 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators
WO2015187840A2 (en) * 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENES & DEVELOPMENT, vol. 14, no. 22, JPN7024004611, 2000, pages 2831 - 2838, ISSN: 0005452648 *
MOLECULAR DIVERSITY, vol. 18, no. 3, JPN7024004612, 2014, pages 545 - 558, ISSN: 0005452649 *

Also Published As

Publication number Publication date
MX2022006151A (es) 2022-08-02
EP4065228A1 (en) 2022-10-05
US11427586B2 (en) 2022-08-30
JOP20220124A1 (ar) 2022-05-23
AU2020394597B2 (en) 2024-03-14
TW202132289A (zh) 2021-09-01
ECSP22040362A (es) 2022-06-30
PY2077235A (es) 2022-10-31
CO2022006645A2 (es) 2022-05-31
PH12022551248A1 (en) 2023-09-11
US20220340573A1 (en) 2022-10-27
UY38964A (es) 2021-06-30
CN114746149A (zh) 2022-07-12
IL291958A (en) 2022-06-01
DOP2022000107A (es) 2022-06-15
AU2020394597A1 (en) 2022-06-02
CL2022001323A1 (es) 2023-03-24
CA3157657A1 (en) 2021-06-03
PE20221785A1 (es) 2022-11-22
WO2021105857A1 (en) 2021-06-03
BR112022009942A2 (pt) 2022-08-09
KR20220106778A (ko) 2022-07-29
CR20220227A (es) 2022-06-15
US20220064164A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
CN112313231B (zh) Oga抑制剂化合物
WO2021047622A1 (zh) 吡啶氮氧化合物及其制备方法和用途
US20220340573A1 (en) 1,2,4-oxadiazole derivatives as liver x receptor agonists
EP2788335B1 (en) 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives for the treatment of disorders in which beta-secretase is involved
JP2020503298A (ja) 単環式ｏｇａ阻害剤化合物
US20200157092A1 (en) [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
KR20130090793A (ko) 베타-세크레타아제(ｂａｃｅ) 저해제로 유용한 5-아미노-3,6-디하이드로-1ｈ-피라진-2-온 유도체
AU2018216040A1 (en) OGA inhibitor compounds
JP2015514073A (ja) スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用
JP2021519269A (ja) ピペラジンアザスピロ誘導体
JP2019532077A (ja) 治療用化合物及びその使用方法
MX2014006689A (es) Derivados de 6-difluorometil-5,6-dihidro-2h-[1,4]oxazin-3-amina.
US20190382349A1 (en) PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT
KR20180044256A (ko) A7-니코틴성 아세틸콜린 수용체의 작용제로서의 아미노벤즈이소옥사졸 화합물
WO2024148308A1 (en) Novel, reversible dpp1 inhibitors and uses thereof
CN117062804A (zh) 1,3-取代的环丁基衍生物及其用途
US20230002366A1 (en) Indene derivatives useful in treating pain and inflammation
CN112292377A (zh) Oga抑制剂化合物
HK1254800A1 (zh) 2，3，4，5-四氢吡啶-6-胺衍生物
US20250213558A1 (en) T-type calcium channel modulators comprising a piperazine or 1,4-diazepane core and methods of use thereof
WO2022249006A1 (en) Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
JP2009517483A (ja) 一酸化窒素シンターゼの二量化の抑制剤としてのイミダゾール誘導体
HK40099374A (en) Piperazine azaspiro derivatives
BR122025005591A2 (pt) Uso de e processo para preparação de derivados de ciclobutila 1,3-substituída, combinação farmacêutica, e kit
BR122025005591B1 (pt) Uso de e processo para preparação de derivados de ciclobutila 1,3- substituída, combinação farmacêutica, e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250430